Jinxin Fertility Group Limited, established in 2003 and headquartered in Chengdu, China, functions as an investment holding company primarily focused on delivering assisted reproductive services (ARS) across both China and the United States. The company offers a comprehensive range of fertility treatments, encompassing artificial insemination, which can be performed using either a husband's or donor sperm, and advanced in vitro fertilization (IVF) techniques such as conventional IVF with embryo transfer or IVF enhanced by intracytoplasmic sperm injection (ICSI). Supporting these core services, Jinxin also provides patients with nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Furthermore, its operations extend to general medical services including gynecology, urology, and internal medicine, along with managing outpatient surgical facilities and various ancillary medical provisions. The group also conducts pre-implantation genetic screening tests and engages in diverse ventures like investment management, management consultancy, and real estate development and operation.
—
Jinxin Fertility Group Limited, established in 2003 and headquartered in Chengdu, China, functions as an investment holding company primarily focused on delivering assisted reproductive services (ARS) across both China and the United States. The company offers a comprehensive range of fertility treatments, encompassing artificial insemination, which can be performed using either a husband's or donor sperm, and advanced in vitro fertilization (IVF) techniques such as conventional IVF with embryo transfer or IVF enhanced by intracytoplasmic sperm injection (ICSI). Supporting these core services, Jinxin also provides patients with nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Furthermore, its operations extend to general medical services including gynecology, urology, and internal medicine, along with managing outpatient surgical facilities and various ancillary medical provisions. The group also conducts pre-implantation genetic screening tests and engages in diverse ventures like investment management, management consultancy, and real estate development and operation.
—
Daily adjusted close
Jinxin Fertility Group Limited, established in 2003 and headquartered in Chengdu, China, functions as an investment holding company primarily focused on delivering assisted reproductive services (ARS) across both China and the United States. The company offers a comprehensive range of fertility treatments, encompassing artificial insemination, which can be performed using either a husband's or donor sperm, and advanced in vitro fertilization (IVF) techniques such as conventional IVF with embryo transfer or IVF enhanced by intracytoplasmic sperm injection (ICSI). Supporting these core services, Jinxin also provides patients with nutritional guidance, traditional Chinese medicine therapies, and psychological counseling. Furthermore, its operations extend to general medical services including gynecology, urology, and internal medicine, along with managing outpatient surgical facilities and various ancillary medical provisions. The group also conducts pre-implantation genetic screening tests and engages in diverse ventures like investment management, management consultancy, and real estate development and operation.